MENU
Showcases Stock ranks Forex

Graf Industrial Corp (GRAF)
  0 (0%) 04-19 11:55
Open: Pre. Close:
High: Low:
Volume: 0 Market Cap: 0(M)
Stock Technical Analysis
Overall:     
Target: Six months: 31.18
One year: 37.96
Support: Support1: 17.30
Support2: 14.39
Resistance: Resistance1: 26.69
Resistance2: 32.50
Pivot: 24.99
Moving Averages: MA(5): 21.82
MA(20): 25.06
MA(100): 16.53
MA(250): 12.71
MACD: MACD(12,26): 0.60
Signal(12,26,9): 1.21
%K %D: %K(14,3): 38.79
%D(3): 25.16
RSI: RSI(14): 55.15
52-Week: High:
Low:
Change(%): 146.3
Average Vol(K): 3-Month: 113991
10-Days: 159822
Prices Prediction (Update @5:00pm)
If tomorrow: Open lower Open higher
High: 25.588 - 25.691 25.691 - 25.798
Low: 22.936 - 23.035 23.035 - 23.137
Close: 24.578 - 24.76 24.76 - 24.947
Price, MAs and Bollinger Bands
Price and moving averages has closed below its Short term moving average. Short term moving average is currently above mid-term; AND above long term moving averages. From the relationship between price and moving averages; we can see that: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.

GRAF has closed above bottom band by 48.1%. Bollinger Bands are 106.2% wider than normal. The large width of the bands suggest high volatility as compared to GRAF's normal range. The bands have been in this wide range for 18 bars. This is a sign that the current trend might continue.
Company profile
Stock chart
Stock News
Tue, 19 Mar 2024
Lana Graf | Principal Industry Specialist, International Finance Corporation (IFC) - World Bank

Fri, 01 Dec 2023
NanoGraf Holds Ribbon Cutting for Midwest's First Advanced Silicon Anode Production Facility - GlobeNewswire

Mon, 02 Oct 2023
NKGen Biotech, Inc. Announces Closing of Business Combination - GlobeNewswire

Thu, 31 Aug 2023
Velodyne SPAC Investor Sues In Chancery Over Merger Flop - Law360

Thu, 31 Aug 2023
Velodyne's Graf-Backed SPAC Deal Draws Challenge From Investor - Bloomberg Law

Fri, 24 Mar 2023
SPACs back from brink with NK cell therapy biotech's plans for blank-check merger - Fierce Biotech

Financial Analysis
Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Neutral
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Neutral
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Neutral
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Stock Basics & Statistics
Exchange: 
Sector: 
Industry: 
Shares Out. (M) 17.55
Shares Float (M) 7.23
% Held by Insiders 5.86
% Held by Institutions 96.21
Shares Short (K) 923
Shares Short Prior Month (K) 596
Stock Financials
EPS -0.560
Book Value (p.s.) 0.280
Profit Margin
Operating Margin
Return on Assets (ttm)
Return on Equity (ttm)
Qtrly Rev. Growth
Gross Profit (p.s.)
Sales Per Share
EBITDA (p.s.)
Qtrly Earnings Growth
Operating Cash Flow (M) -1.18
Levered Free Cash Flow (M)
Stock Valuation
PE Ratio -44.20
PEG Ratio
Price to Book value 88.39
Price to Sales
Price to Cash Flow -368.10
Stock Dividends
Dividend
Dividend Yield
Dividend Growth

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android